Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 11—November 2015
CME ACTIVITY - Synopsis

Uncommon Candida Species Fungemia among Cancer Patients, Houston, Texas, USA

Dong Sik Jung1, Dimitrios Farmakiotis12, Ying Jiang, Jeffrey J. Tarrand, and Dimitrios P. KontoyiannisComments to Author 
Author affiliations: Dong-A University College of Medicine, Busan, South Korea (D.S. Jung); The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (D.S. Jung, D. Farmakiotis, Y. Jiang, J.J. Tarrand, D.P. Kontoyiannis); Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts, USA (D. Farmakiotis)

Main Article

Figure 2

Increasing annual use of echinocandin antifungal drugs at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA, January 2001–September 2013. Spearman’s correlation coefficient r = 0.98, p<0.0001. DDD, defined daily doses.

Figure 2. Increasing annual use of echinocandin antifungal drugs at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA, January 2001–September 2013. Spearman’s correlation coefficient r = 0.98, p<0.0001. DDD, defined daily doses.

Main Article

1These authors contributed equally to this article.

2Current affiliation: Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.

Page created: October 19, 2015
Page updated: October 19, 2015
Page reviewed: October 19, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external